Our Lead Programs

We are currently advancing a pipeline of novel NAD-boosting compounds:

MIB-626

Our lead drug candidate, MIB-626, is a novel, patented crystalline NAD+ booster with scalable manufacturing capabilities. It is currently in three Phase 2 clinical trials for Alzheimer’s disease, chronic kidney disease, and muscle strength and endurance.

MIB-725

A next-generation NAD+ precursor that will be under investigation for acute kidney injury (AKI) following cardiac surgery.

Phase 1 safety and bioavailability studies commenced in Q1 2025.

In addition, we are progressing clinical development  in multiple related areas:

01 Muscle Strength Trials

Enrollment concluded for a key study with results anticipated later this year.

02 Alzheimer’s Disease

A Phase 2a trial is underway, with recruitment completed and preliminary data from the study being available possible by year-end. Ongoing studies are addressing mild cognitive impairment and early dementia.

03 Diabetic Kidney Disease

Our DKD program has expanded to three clinical sites, including a new location in Los Angeles; primary readout expected in 2026.